New Zealand markets closed

Hillstream BioPharma, Inc. (HILS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.4004-0.0002 (-0.05%)
At close: 12:57PM EST
0.4199 +0.02 (+4.87%)
After hours: 04:00PM EST

Hillstream BioPharma, Inc.

1200 Route 22 East
Suite 2000
Bridgewater, NJ 08807
United States
908 955 3140
https://www.hillstreambio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees1

Key executives

NameTitlePayExercisedYear born
Mr. Randy D. Milby MBAPres, Chairman & CEON/AN/A1954
Mr. Thomas P. Hess CPA, MBAChief Financial OfficerN/AN/A1964
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Corporate governance

Hillstream BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.